CATX

BMO Capital Markets initiated coverage of Perspective Therapeutics with a rating of Outperform and set a new price target of $11.00

10-Q - Perspective Therapeutics, Inc. (0000728387) (Filer)

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

Advancing VMT-α-NET toward a Phase 3 study in neuroendocrine tumors, subject to regulatory alignment: regulatory engagement ongoing; clinical site activation targeted around year-end 2026 subject to regulatory feedback; sufficient isotope access and manufacturing capacityVMT-α-NET study update accepted for oral presentation at ESMO 2026VMT01 melanoma and PSV359 FAP-α clinical programs continue to advanceApproximately $237 million in cash, cash equivalents, and short-term investments as of June 30, 2026; expected to be sufficient to fund current planned clinical milestones and operational investments into late 2027 SEATTLE, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (

SCHEDULE 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

SEATTLE, July 31, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will report its second quarter 2026 financial results and provide a business update on Monday, August 10, 2026 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases. About Perspective Therapeutics, Inc. Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throu

European orphan medicinal product designation granted for [²¹²Pb]VMT-α-NET for the treatment of GEP-NETs[²¹²Pb]VMT-α-NET is being evaluated in an ongoing Phase 1/2a study in patients with SSTR2-positive neuroendocrine tumors; interim clinical data support [212Pb]VMT-α-NET’s potential to provide significant benefit relative to approved therapies for European patients living with GEP-NETs Designation provides development and potential commercial incentives to support the advancement of [²¹²Pb]VMT-α-NET in Europe SEATTLE, July 28, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development com

SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026. PresenterAbstract TitlePresentation DetailsThorvardur Halfdanarson, Mayo Clinic Comprehensive Cancer CenterCohort level s

SEATTLE, July 08, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced the appointment of Paul Lyne, Ph.D., as Chief Science Officer. The Company also announced that Michael K. Schultz, Ph.D., co-founder and the Company’s long-time Chief Science Officer, has transitioned to the role of Senior Scientific Advisor & Co-Founder as part of a planned transition toward retirement. "It is impossible to overstate the impact Michael Schultz has had on Perspective," said Thijs Spoor, Perspective’s CEO. "Togeth

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

SEATTLE, June 03, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that the first meningioma patient was dosed with [212Pb]VMT-α-NET in the Company's ongoing Phase 1/2a study. The new cohort is intended to evaluate the safety, dosimetry, and preliminary anti-tumor activity of lead-based alpha-particle therapy with [212Pb]VMT-α-NET for meningioma (LEMONαDE). The initiation of the meningioma cohort reflects The Company's broader strategy to evaluate [212Pb]VMT-α-NET across somatostatin receptor su

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily pre-treated melanoma; further data expected in late 2026[²¹²Pb]PSV359 advanced to Cohort 3 of the Phase 1/2a study in FAP-expressing solid tumors; initial safety findings in lower dose cohorts were Grades 1 and 2 only, with no DLTs and no discontinuation due to adverse events; further data expected in late 2026Updated [212Pb]VMT-α-NET interim efficacy (n=25) and safety data (n=68) as of April 17, 2026, were consistent with previously disclosed findings at AACR as of March 4, 2026 with continued deepening

SEATTLE, May 18, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that the first patients were dosed with [212Pb]VMT-α-NET and [212Pb]PSV359 in two new cohorts of Phase 1/2a studies in neuroendocrine tumors and solid tumors, respectively. The first patient was treated with [212Pb]VMT-α-NET in a fourth cohort of the Company's ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs)

10-Q - Perspective Therapeutics, Inc. (0000728387) (Filer)

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

Differentiated ²¹²Pb radiopharmaceutical platform designed to optimize tumor killing, safety, patient convenience and supply scalabilityThree clinical-stage oncology programs advancing across neuroendocrine tumors, melanoma and FAP-positive solid tumors with multiple clinical catalysts expected in 2026 across VMT-α-NET, VMT01 and PSV359 programs; lead program, VMT-α-NET, advancing toward a registration-enabling studyRegional manufacturing network designed to support reliable supply of ready-to-administer radiopharmaceuticals for clinical development and potential commercialization; Chicago site expected to complete construction in 2026 Cash runway expected into late 2027 to support planned c

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

SEATTLE, April 24, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will provide several corporate updates in May 2026. Webcasts of these events, unless noted as press release only, will be posted on the Company's website at www.perspectivetherapeutics.com. Analyst Event on Perspective's Strategy, Enabling Technology, and PipelineAdditional details are available here.Date: May 4, 2026Time: 8:30 a.m. ET First Quarter 2026 Financial Results – Press Release OnlyThe press release will be available on the newsro

8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)

Updated interim results with an additional ~12 weeks of follow-up since prior update at ASCO-GI in January 2026 and ~25 weeks since ESMO in October 2025Safety update presented on all 64 patients who received at least one treatment and updated efficacy analysis presented on the two patients in Cohort 1 and 23 patients in Cohort 2Objective response in 43% (10 out of 23) of patients in first half of Cohort 2, including an additional new response and confirmation of the initial response reported at ASCO-GI 2026Nine patients experienced deepening of response since the ESMO presentation [212Pb]VMT-α-NET continues to be well-tolerated Initial efficacy data from additional 23 patients in Cohort 2 an

DEFA14A - Perspective Therapeutics, Inc. (0000728387) (Filer)

DEF 14A - Perspective Therapeutics, Inc. (0000728387) (Filer)